Lord Mendelsohn

To ask Her Majesty's Government how many people who are immunocompromised or immunosuppressed have received a third dose of a COVID-19 vaccine in England to date.

To ask Her Majesty's Government what plans they have to protect the (1) primary, and (2) secondary, immunodeficiency community against COVID-19 this winter.

To ask Her Majesty's Government what changes they have made to the commissioning eligibility criteria for immunoglobulin use since the identification of a shortage of immunoglobulin; and (1) when, and (2) how, these will be implemented.

To ask Her Majesty's Government how much the NHS has invested in multi-parametric magnetic resonance imaging scanners in the last three years.

To ask Her Majesty's Government how many multi-parametric magnetic resonance imaging scans are in use in each Cancer Alliance.

To ask Her Majesty's Government what steps they are taking to ensure people who are immunosuppressed or immunocompromised receive clear communication regarding their risk from the Omicron variant of COVID-19 and the steps they can take to mitigate that ri...

To ask Her Majesty's Government what are the (1) planned order quantities, and (2) delivery dates, for the COVID-19 antibody drugs Molnupiravir and Ritonavir; and what is the (a) current, and (b) planned, geographic distribution of Molnupiravir and Ritona...

To ask Her Majesty's Government what steps they are taking to address staff capacity issues within the Medicines and Healthcare products Regulatory Agency to ensure that patients get treatments in a timely manner.

To ask Her Majesty's Government how many multi-parametric magnetic resonance imaging scans have been carried out to investigate cases of suspected prostate cancer in England in each year since 2016.

To ask Her Majesty's Government what communications have been issued by the NHS in England about the immunoglobulin shortage to patient groups supporting people with immunodeficiency; and whether the NHS in England has communicated directly with patients ...

To ask Her Majesty's Government how the NHS in England is monitoring the health outcomes of patients who no longer fit the new eligibility criteria for immunoglobulin use.

To ask Her Majesty's Government when they expect patients to receive treatment with products made from UK plasma.

To ask Her Majesty's Government why they have not yet appointed a supplier of immunoglobulin products; and when they expect to have completed the tender process.

To ask Her Majesty's Government what assessment they have made of the benefits of testing the antibody levels of immunosuppressed or immunocompromised individuals given the spread of the Omicron variant of COVID-19.

To ask Her Majesty's Government what plans they have to monitor (1) immunocompromised patients' antibody levels, and (2) their variation over time, in response to the rollout of the third primary dose vaccination.

To ask Her Majesty's Government how many challenges have been made to the sub-regional immunoglobulin assessment panels in the last year concerning access to immunoglobulin therapy; and how many decisions have been overturned.

To ask Her Majesty's Government how the NHS is monitoring (1) the health of patients who (a) have been denied access to immunoglobulin therapy or (b) are on sub-optimal care in relation to immunoglobulin therapy, and (2) the additional cost of patients (a...

To ask Her Majesty's Government how many patients in the last year have (1) been taken off therapy, (2) had to change immunoglobulin product, (3) been advised of treatment holidays, or (4) received reduced doses, because of a shortage of immunoglobulin.

To ask Her Majesty's Government when Ronapreve will be available for (1) immunocompromised patients unlikely to mount a vaccine response, and (2) patients at higher risk of poorer COVID-19 outcomes prior to hospitalisation.

To ask Her Majesty's Government how many newly-diagnosed patients with (1) primary or (2) secondary immunodeficiency in the UK, who fit the eligibility criteria for immunoglobulin use, have been refused access to immunoglobulin this year.